Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Endocrine therapy and endocrine resistant breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.05.12
Views: 3783
Rating:

Prof Mitch Dowsett – The Institute for Cancer Research, London, UK

Prof Mitch Dowsett talks to ecancer about important papers presented at IMPAKT 2012 in Brussels, May 2012, on endocrine therapy, drug resistance, cell cycling and combination therapy.

 

Prof Dowsett discusses findings on everolimus, data from the BOLERO-2 study, which was presented by Prof Jose Baselga, and the outcomes from a phase 2 study involving CDK inhibitors.

 

Filming Supported by Amgen

Related videos

follow us

Breast Cancer CDK 4/6


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation